- Marketwired•10 months agoIntellect Neurosciences, Inc. Engages Benjamin D. Freilich, MD, FACS as Senior Medical Affairs Advisor for CONJUMAB-A Antibody Drug Conjugate Program
Intellect Neurosciences, Inc. , a research-based biotechnology company focused on the discovery, development and licensing of novel disease-modifying therapeutics for the treatment and prevention of rare ...
- Marketwired•last year
Intellect Neurosciences, Inc. , a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of rare neurodegenerative......
- Marketwired•last yearIntellect Neurosciences, Inc. Engages Troy Rohn, PhD as Lead Scientific Advisor for TauC3 Antibody Program
Intellect Neurosciences, Inc. a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of rare neurodegenerative conditions, ...
ILNS : Summary for INTELLECT NEUROSCI COM USD0.001 - Yahoo Finance
Intellect Neurosciences, Inc. (ILNS)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.01 - 0.02|
|52 Week Range||0.01 - 0.05|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||0.26|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|